| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/31/2000 | EP1003555A1 Controlled release of ophthalmic compositions |
| 05/31/2000 | EP1003554A1 Proton pump inhibitor in therapeutic combination with antibacterial substances |
| 05/31/2000 | EP1003550A1 Receptor specific transepithelial transport of therapeutics |
| 05/31/2000 | EP1003545A1 Heparin-binding growth factor (hbgf) polypeptides |
| 05/31/2000 | EP1003544A1 C1q AND COLLECTIN RECEPTOR |
| 05/31/2000 | EP1003542A1 Use of substances having oxytocin activity for preparation of medicaments for wound healing |
| 05/31/2000 | EP1003540A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 05/31/2000 | EP1003530A1 Eye treatments using synthetic thyroid hormone compositions |
| 05/31/2000 | EP1003526A1 Covalently linked n,o-carboxymethylchitosan and uses thereof |
| 05/31/2000 | EP1003518A1 A method for the treatment of mental illness in mammals and a composition therefor |
| 05/31/2000 | EP1003507A1 Combination therapy comprising amlodipine and a statin compound |
| 05/31/2000 | EP1003492A2 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins |
| 05/31/2000 | EP1003491A1 Use of antagonists or partial agonists of the vanilloid receptor complexes for treating neurodegenerative diseases |
| 05/31/2000 | EP1003487A1 Novel pharmaceutical formulation with controlled release of active substances |
| 05/31/2000 | EP1003476A1 Prolonged release active agent dosage form adapted for gastric retention |
| 05/31/2000 | EP1003474A1 Method of treating dry eye disease with purinergic receptor agonists |
| 05/31/2000 | EP1003373A1 Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| 05/31/2000 | EP0939651B1 Materials and methods relating to the diagnosis and treatment of pre-eclampsia |
| 05/31/2000 | EP0747033B1 Transfusion liquid-containing holder and prepared transfusion liquid |
| 05/31/2000 | DE19854403A1 Phosphororganische Verbindungen und ihre Verwendung Organophosphorus compounds and their use |
| 05/31/2000 | CN1255164A Modified antisense nucleotides complementary to section of human Ha-Ras gene |
| 05/31/2000 | CN1255064A Use of 'alpha'-methyl-P-tyrosine to inhibit melanin production in iris melanocytes |
| 05/31/2000 | CN1255063A Photosensitizer conjugates for pathogen targeting |
| 05/31/2000 | CN1255041A Methods and compositions for treatment of aids-associated kaposi's sarcoma |
| 05/30/2000 | US6069239 Expression system present in compatible host cell which produces a ligand regulated transcription factor; antiinflammatory/antiarthritic/antidiabetic agents; treatment of autoimmune diseases; diagnosis of related diseases |
| 05/30/2000 | US6069174 Protein kinase C activators and their use in increasing expression of cell antigens |
| 05/30/2000 | US6069169 Dermatologic and cosmetic use for oxa acids |
| 05/30/2000 | US6069168 Compositions for treatment of diabetic complications |
| 05/30/2000 | US6069164 Methods for treating circadian rhythm phase disturbances |
| 05/30/2000 | US6069135 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents |
| 05/30/2000 | US6069134 Methods and compositions comprising DNA damaging agents and p53 |
| 05/30/2000 | US6069133 Targeted delivery of genes encoding interferon |
| 05/30/2000 | US6069006 Connective tissue growth factor (CTGF) regulatory nucleic acid sequences |
| 05/30/2000 | US6068972 Screening by contacting microorganisms with organic solvent, determining expression of acr-like efflux pump gene locus, comparing to control, altered expression indicates activation of multiple antibiotic resistance phenotype |
| 05/30/2000 | US6068856 Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| 05/30/2000 | US6068851 Formulation for use in the prevention of pathogen induced diseases including HIV and HSV |
| 05/30/2000 | CA2159326C Method for treating amyloidosis |
| 05/26/2000 | CA2252966A1 Viral therapeutics |
| 05/25/2000 | WO2000029846A2 COMPOSITIONS AND METHODS RELATING TO THE PEROXISOMAL PROLIFERATOR ACTIVATED RECEPTOR-α MEDIATED PATHWAY |
| 05/25/2000 | WO2000029620A1 Methods of facilitating vascular growth |
| 05/25/2000 | WO2000029599A1 Viral vectors with late transgene expression |
| 05/25/2000 | WO2000029590A1 Method for identifying inhibitors of ipc synthase |
| 05/25/2000 | WO2000029580A1 Calcium binding protein |
| 05/25/2000 | WO2000029577A1 Novel members of the capsaicin/vanilloid receptor family of proteins and uses thereof |
| 05/25/2000 | WO2000029569A1 Methods of diagnosing or treating neurological diseases |
| 05/25/2000 | WO2000029438A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 05/25/2000 | WO2000029030A1 Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions |
| 05/25/2000 | WO2000029029A1 Compositions and methods for producing vascular occlusion |
| 05/25/2000 | WO2000029023A1 Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| 05/25/2000 | WO2000029022A1 Cox-2 inhibitors in combination with centrally acting analgesics |
| 05/25/2000 | WO2000029020A1 Anti-icam-r antibody-induced apoptosis |
| 05/25/2000 | WO2000029015A2 INFLUENCING OF ANGIGENESIS USING CD66a |
| 05/25/2000 | WO2000029011A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 05/25/2000 | WO2000029008A2 Hiv-specific t-cell induction |
| 05/25/2000 | WO2000029001A1 Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation |
| 05/25/2000 | WO2000028999A2 Methods of treating tardive dyskinesia and other movement disorders |
| 05/25/2000 | WO2000028990A1 Pharmaceutical composition for modified release insulin sensitiser |
| 05/25/2000 | WO2000028989A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 05/25/2000 | WO2000028988A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| 05/25/2000 | WO2000028981A2 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 05/25/2000 | WO2000028980A2 Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain |
| 05/25/2000 | WO2000028968A1 Drug delivery device, especially for the delivery of progestins and estrogens |
| 05/25/2000 | WO2000028947A2 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
| 05/25/2000 | WO2000028942A1 Process for the manufacture of liquid filled capsules |
| 05/25/2000 | WO2000028821A1 Therapeutic anti-fungal nail preparation |
| 05/25/2000 | WO2000016761A3 Serotonergic 5ht2 agonists for treating glaucoma |
| 05/25/2000 | WO2000015247A3 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| 05/25/2000 | WO2000015207A3 Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) |
| 05/25/2000 | WO2000012111A3 Selective treatment of endothelial somatostatin receptors |
| 05/25/2000 | WO2000004884A9 Pharmaceutical preparations for the topical treatment of mucocutaneous herpes infections and herpetic keratitis of the eye |
| 05/25/2000 | WO2000001410A9 Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| 05/25/2000 | WO2000000825A9 Detection and modulation of cellular immunity to immune privileged antigens |
| 05/25/2000 | CA2351585A1 Influencing of angigenesis using cd66a |
| 05/25/2000 | CA2351522A1 Egf-like nucleic acids and polypeptides and uses thereof |
| 05/25/2000 | CA2351224A1 Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| 05/25/2000 | CA2351058A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 05/25/2000 | CA2350914A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 05/25/2000 | CA2350911A1 Hiv-specific t-cell induction |
| 05/25/2000 | CA2350531A1 Method for treating pain |
| 05/25/2000 | CA2350420A1 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor |
| 05/25/2000 | CA2350389A1 Calcium binding protein |
| 05/25/2000 | CA2349919A1 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress |
| 05/25/2000 | CA2349618A1 Compositions and methods relating to the peroxisomal proliferator activated receptor-.alpha. mediated pathway |
| 05/25/2000 | CA2349581A1 Anti-icam-r antibody-induced apoptosis |
| 05/25/2000 | CA2349575A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| 05/25/2000 | CA2348781A1 Compositions and methods for producing vascular occlusion |
| 05/25/2000 | CA2348479A1 Novel members of the capsaicin/vanilloid receptor family of proteins and uses thereof |
| 05/25/2000 | CA2347914A1 Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation |
| 05/25/2000 | CA2340468A1 Methods of facilitating vascular growth |
| 05/24/2000 | EP1002870A1 Androgen- and progesteron-receptor binding Hormone Response Element |
| 05/24/2000 | EP1002862A1 Methods of diagnosing or treating neurological diseases |
| 05/24/2000 | EP1002805A1 Fixation inhibitors for helicobacter pylori |
| 05/24/2000 | EP1002547A1 Hydrosoluble hedgehog protein in ionic complex and pharmaceutical use thereof |
| 05/24/2000 | EP1002543A1 Pharmaceutical compositions for the therapy of glioma or prostate cell proliferative disorders containing cyclic rgd compounds |
| 05/24/2000 | EP1002542A1 Method for treating the endotoxic shock in mammals |
| 05/24/2000 | EP1002535A1 New use of glutamate antagonists for the treatment of cancer |
| 05/24/2000 | EP1002531A1 A water-miscible composition of non-steroidal antiinflammatory drugs |
| 05/24/2000 | EP1002099A1 Synaptojanin isoform |
| 05/24/2000 | EP1002078A1 Method enabling readministration of aav vector via immunosuppresion of host |
| 05/24/2000 | EP1002073A2 Cell activation process and reagents therefor |